Get it on Google Play

Kairos Pharma reports positive interim data for prostate cancer drug

October 6, 2026 7:30 AM EDT Send to a Friend
Kairos Pharma, Ltd. (NYSE American: KAPA) announced positive interim efficacy data from its ongoing Phase 2 clinical trial evaluating ENV-105 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login